MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Epithelioid

Epitheliod mesothelioma makes up between 50% and 70% of all diagnosed cases of mesothelioma; it also tends to have the best prognosis.

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Journal of Clinical Oncology 2019 August 6 [Link] Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K Abstract PURPOSE: Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib […]

Comments Off on Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Molecular characterization of localized pleural mesothelioma.

Molecular Pathology 2019 August 1 [Link] Hung YP, Dong F, Dubuc AM, Dal Cin P, Bueno R, Chirieac LR Abstract Localized pleural mesothelioma is a rare solitary circumscribed pleural tumor that is microscopically similar to diffuse malignant pleural mesothelioma. However, the molecular characteristics and nosologic relationship with its diffuse counterpart remain unknown. In a consecutive […]

Comments Off on Molecular characterization of localized pleural mesothelioma.

Heterologous sarcomatoid pleural mesothelioma with osteosarcomatous differentiation: a report of autopsy case that accomplished trimodality therapy and review of the literature.

General Thoracic and Cardiovascular Therapy 2019 August 1 [Link] Itano H, Takeda T, Yamada T, Koide M, Kobayashi T Abstract Heterologous mesothelioma is a very rare subtype of sarcomatoid mesothelioma characterized by the presence of malignant heterologous elements. A 69-year-old man with a strong history of asbestos exposure presented with a 5-cm mass in his […]

Comments Off on Heterologous sarcomatoid pleural mesothelioma with osteosarcomatous differentiation: a report of autopsy case that accomplished trimodality therapy and review of the literature.

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.

Clinical Lung Cancer 2019 May 13 [Link] Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G Abstract BACKGROUND: Anticancer immune responses are negatively regulated […]

Comments Off on Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.

The Prevalence and Clinical Relevance of Non-expandable Lung in Malignant Pleural Mesothelioma: A Prospective, Single-Center Cohort Study of 229 Patients.

Annals of the American Thoracic Society 2019 June 12 [Link] Bibby AC, Halford P, De Fonseka D, Morley AJ, Smith S, Maskell NA Abstract RATIONALE: Non-expandable lung is a recognised phenomenon that can create management challenges in mesothelioma. Its prevalence and clinical importance are unknown. OBJECTIVE: The aim of this study was to describe the […]

Comments Off on The Prevalence and Clinical Relevance of Non-expandable Lung in Malignant Pleural Mesothelioma: A Prospective, Single-Center Cohort Study of 229 Patients.

Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT).

Clinical Cancer Research 2019 June 4 [Link] Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor […]

Comments Off on Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT).

Diagnostic Value of BAP1, GLUT-1 and Desmin Expression in the Discrimination Between Reactive Mesothelial Proliferation and Malignant Mesothelioma in Tissues and Effusions.

Cytopathology 2019 June 5 [Link] Önder S, Özogul E, Koksal D, Sarinc Ulasli S, Firat P, Emri S Abstract OBJECTIVE: The aim of this study was to investigate the utility of BAP1, GLUT-1 and desmin expression by immunohistochemistry in the discrimination between reactive and malignant mesothelial proliferations. METHODS: A total of 88 biopsies and 30 […]

Comments Off on Diagnostic Value of BAP1, GLUT-1 and Desmin Expression in the Discrimination Between Reactive Mesothelial Proliferation and Malignant Mesothelioma in Tissues and Effusions.

Signet ring cell mesothelioma; A diagnostic challenge

Pathology Research and Practice 2019 May 22 [Link] Wang H, Herath C Abstract Signet ring cell mesothelioma is a rare variant of epithelioid mesothelioma with limited cases published. It has a male predilection and most commonly occurs on pleura; it can also arise in the peritoneal cavity. The signet ring cell morphology can pose a […]

Comments Off on Signet ring cell mesothelioma; A diagnostic challenge

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

The Lancet. Respiratory Medicine. 2019 May 15 [Link] Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim […]

Comments Off on Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.

BMJ Open 2019 May 14 [Link] de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts JGJV, Madsen EVE Abstract INTRODUCTION: Malignant peritoneal mesothelioma (MPM) is an uncommon but aggressive neoplasm and has a strong association with asbestos exposure. MPM has low survival rates of approximately 1 year even after (palliative) surgery and/or systemic chemotherapy. […]

Comments Off on Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.